Levitee Labs appoints Dr Fady Hannah-Shmouni as its chief medical and scientific officer and president of Levitee Clinics and Pharmacies

5 August, 2021

Levitee Labs appoints Dr Fady Hannah-Shmouni as its chief medical and scientific officer and president of Levitee Clinics and Pharmacies

Dr Hannah-Shmouni – a leading expert in neuroendocrinology and genetics from the United States’ National Institutes of Health (NIH) – will oversee Levitee Labs’ medical affairs, research activities, and corporate medical strategy

Handshake
He will also work with relevant parties to provide oversight of Levitee Labs’ clinical and scientific agenda and partnerships with a special focus on mental illness treatment, including substance use and pain disorders

Levitee Labs (CSE:LVT) Inc. has announced the appointment of Dr Fady Hannah-Shmouni as the company’s chief medical and scientific officer and president of Levitee Clinics and Pharmacies.

In this role, Dr Hannah-Shmouni – a leading expert in neuroendocrinology and genetics from the United States’ National Institutes of Health (NIH) – will oversee Levitee Labs’ medical affairs, research activities, and corporate medical strategy. He will also work with relevant parties to provide oversight of Levitee Labs’ clinical and scientific agenda and partnerships with a special focus on mental illness treatment, including substance use and pain disorders.

READ: Levitee Labs completes acquisition of superfoods provider Earth Circle Organics Chain

“A practicing internist, neuroendocrinologist and geneticist coming from the world’s top scientific research institution, Dr Hannah-Shmouni brings the complete package to our company. His depth of knowledge and experience in clinical and lab research, academia, administration, as well as deep understanding of public, private and government sectors will support significant growth of our integrative wellness portfolio,” said Pouya Farmand, chief executive officer at Levitee Labs in a statement.

“Dr Hannah-Shmouni coming onboard as Chief Medical and Scientific Officer is testament to our vision and growing portfolio of assets attracting top talent and representative of our commitment to operational and executional excellence. He will be instrumental in leading our research initiatives, as well as our growth strategies to expand our health-related initiatives throughout Canada and internationally,” he added.

Prior to joining Levitee Labs, Dr Hannah-Shmouni was a clinician-scientist in neuroendocrinology, hypertension, and biochemical genetics at NIH (Maryland, USA) since 2015. He served as director of the Office of Education’s Graduate Medical Education (GME) with the National Institute of Child Health and Human Development; Chief of the Internal Medicine, Endocrinology, and Genetics Inpatient Ward; Associate Program Director of NIH’s Inter-Institutes Endocrinology & Metabolism Fellowship Program; and Principal Investigator of neuroendocrine genetic and hypertension disorders. In his role as GME Director, Dr Hannah-Shmouni was responsible for overseeing the administrative and academic quality of all clinical training programs within the institute, ensuring national compliance and implementation of effective policies and procedures.

“I am thrilled to be a part of the Levitee Labs team and to use my medical and research experience from NIH to actively study psychedelic medicines for multiple indications, including substance use disorders and chronic pain through innovative research and development,” said Dr. Hannah-Shmouni.

“As an internist and neuroendocrinologist, I look forward to leading future investigations of neuroendocrine system involvement in the long-term therapeutic potential of psychedelic drugs, a field of study that has traditionally been widely overlooked. I am excited to develop comprehensive, multidisciplinary, patient-centered treatment programs through the inclusion of psychedelic therapies to help address the growing crisis of mental health, pain, and addiction,” he added.

Clinical insights on the prolonged effects of stress that can lead to mental health disorders

Dr Hannah-Shmouni specializes in neurohormonal dysregulation of the stress system, with a clinical focus on studying the effects of psychedelic therapies on endocrine conditions and different hormone axes. This specialization in stress hormones uniquely positions Dr Hannah-Shmouni to provide clinical insights on the prolonged effects of stress that can lead to mental health disorders.

He completed his clinical training in internal medicine at the Yale-New Haven Medical Center Program in Yale’s School of Medicine; adult endocrinology, diabetes, and metabolism at NIH; and clinical biochemical genetics at the University of Toronto’s Hospital for Sick Children. He is board-certified in internal medicine, endocrinology, and metabolism by the American Board of Internal Medicine and the Royal College of Physician and Surgeons of Canada; and in clinical hypertension by the American Society of Hypertension. Dr. Hannah-Shmouni is licensed to practice medicine in Canada (British Columbia, Ontario) and the USA.

Dr Hannah-Shmouni is a fellow with the Royal College of Physicians and Surgeons of Canada and an active committee member of the Endocrine Society, International Society of Hypertension, Hypertension Canada Clinical Practice Guidelines, and is the vice-chair of the Pituitary, Gonad, Adrenal and Neuroendocrine Resource Center of the American Association of Clinical Endocrinology. Dr. Hannah-Shmouni is also the Editor-In-Chief of Endocrine and Metabolic Science (Elsevier), and has authored or co-authored over 100 original articles, reviews and book chapters on neuroendocrine, genetic and metabolic conditions.

Levitee Labs is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, it aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies.

The company’s current portfolio of assets includes: Sporeo Supply, the first commercial-grade offering of spawn and substrate that has mass distribution; MONKE Nutraceuticals, a company specialized in developing and distributing premium functional mushroom supplements sold via online portals; ACT Medical Centres, a group of five operating pain and addiction treatment clinics in Alberta; Block MD, the first telemedicine company in Alberta to receive provincial approval for telemedicine prescriptions in the addiction treatment space; three pharmacies operating in Alberta specialized in filling prescriptions for patients with substance abuse disorders, mental health conditions, and chronic pain; and Earth Circle Organics, a direct-to-consumer and wholesaler of supplements and superfood products with 180+ SKUs in its product lineup across three brands.

Contact the author at jon.hopkins@proactiveinvestors.com

via https://ca.proactiveinvestors.com/companies/news/956994/levitee-labs-appoints-drfady-hannah-shmouni-as-its-chief-medical-and-scientific-officer-and-president-of-levitee-clinics-and-pharmacies-956994.html

Would you like to know more?

Contact us